MONMOUTHJUNCTION, NJ, April17,2018 -- Biotech Support Group reports on a recent research articledescribingthe simplicity and efficiency of their hemoglobin depletiontechnology for enriching the red cell proteome, from human red bloodcells.

Thecitation is:

Nemkov,Travis, et al. "Hypoxiamodulates the purine salvage pathway and decreases red blood cell andsupernatant levels of hypoxanthine during refrigerated storage."haematologica103.2 (2018): 361-372.

Thegoal of this study was to use proteomics in part to understandhypoxanthine catabolism invivofor stored red blood cells. It is still unclear whether accumulationof hypoxanthine in stored red blood cell units is clinically relevantfor transfused recipients. Thearticle states “Leukocyte-reducedhuman RBC from healthy donor volunteers were washed five times inphosphate-buffered saline prior to lysis in distilled water withsonication. Proteomic analyses of RBC membranes and cytosols wereperformed…RBC cytosolic proteins were depleted of hemoglobin usingHemovoid™ (Biotech Support Group, Monmouth Junction, NJ, USA),prior to high-pH reversed phase fractionation”.The authors conclude that hypoxiainvitroand invivodecreased purine oxidation and enhanced purine salvage reactions inhuman and mouse red blood cells, which was partly explained bydecreased adenosine monophosphate deaminase activity. The authorsconcluded that hypoxanthine is an invitrometabolic marker of the red blood cell storage lesion that negativelycorrelates with post-transfusion recovery invivo.Storage-dependent hypoxanthine accumulation is ameliorated byhypoxia-induced decreases in purine deamination reaction rates.

“Thisarticle illustrates that our proteomic enrichment products work veryefficiently without the reliance on antibodies. The ability to enrichfor the underlying sub-proteome from the cytosolic fraction of redcells is a unique feature of HemoVoid™. That an extensive list ofproteins were identified by nano-UHPLC-MS/MSdemonstrates itsusefulness in proteomic investigations” states Swapan Roy, Ph.D.,President and Founder of Biotech Support Group. 

Formore information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com

Contact:
MatthewKuruc 732-274-2866, [email protected]